TVTX - Travere Therapeutics Inc. (TVTX) Q4 2023 Earnings Call Transcript

2024-02-16 05:05:19 ET

Travere Therapeutics, Inc. (TVTX)

Q4 2023 Earnings Conference Call

February 15, 2024 16:30 ET

Company Participants

Anne Crotteau - Investor Relations

Eric Dube - Chief Executive Officer

Jula Inrig - Chief Medical Officer

Peter Heerma - Chief Commercial Officer

Chris Cline - Chief Financial Officer

Bill Rote - Senior Vice President of Research & Development

Conference Call Participants

Joseph Schwartz - Leerink Partners

Greg Harrison - Bank of America

Anupam Rama - JP Morgan

Tyler Van Buren - TD Cowen

Carter Gould - Barclays

Maury Raycroft - Jefferies

Liisa Bayko - Evercore ISI

Vamil Divan - Guggenheim Securities

Alex Thompson - Stifel

Ed Arce - H.C. Wainwright & Company

Laura Chico - Wedbush Securities

Presentation

Operator

Good day and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded.

At this time, I would like to turn the conference call over to Anne Crotteau. Please go ahead, ma'am.

Anne Crotteau

Thanks, Jenny. Good afternoon and welcome to Travere Therapeutics fourth quarter and full year 2023 financial results and corporate update call. Thank you all for joining. Today's call will be led by our President and Chief Executive Officer, Dr. Eric Dube. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer; Dr. Bill Rote, Senior Vice President of Research and Development, will join up for the Q&A session.

Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, performance and achievements to differ materially from those expressed or implied by the statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today as well as the Risk Factors section in our Form 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made, February 15, 2024 and Travere specifically disclaims any obligation to update such statements to reflect future information, events or circumstances.

With that, let me now turn the call over to Eric. Eric?

Eric Dube

Thank you, Anne and welcome, everyone. 2023 was a year of many great achievements for Travere as we work towards our goal of breaking down barriers and treating rare diseases with historically little innovation. At the start of 2023, we gained the first approval from our pipeline, delivering sparsentan or FILSPARI, as the first and only non-immunosuppressive treatment option for people living with IgA nephropathy or IgAN. For decades, people living with IgAN, most of whom are diagnosed in their 20s and 30s and on average face kidney failure in 10 years had limited treatment options.

We are proud to help lead the growing evolution of the treatment paradigm that we believe will ultimately see patients get diagnosed and initiate treatment earlier and where physicians will ultimately utilize FILSPARI as a foundational treatment with its superior proteinuria reduction and accrual of kidney preservation benefit....

For further details see: